Long-acting GHRH analogue research

CJC-1295 with DAC

DAC-modified GHRH analogue studied for sustained receptor exposure and albumin binding.

Explore presentation-specific analytical records covering identity, purity, measured content, lot traceability and downloadable Certificates of Analysis.

Certified presentations
Product information
Royal Pharma CJC-1295 with DAC vial
Selected record5 mg

Product-family image supplied by Royal Pharma. Certified presentations are identified by their individual COA records below.

Product authentication

Authenticity, built into every product.

Powered by NFC. Secured by blockchain. Verified instantly.

Each Royal Pharma product carries a unique NFC-enabled microchip connected to the brand's proprietary blockchain authentication environment, creating a secure, traceable and tamper-resistant digital identity.

01
Unique identity

A product-linked NFC identity designed for one-tap verification.

02
Secure verification

A blockchain-secured record supporting authenticity and traceability.

03
Batch documentation

Presentation-specific COAs document identity, purity, measured content and lot information.

Product information

Sustained GHRH analogue research, documented by batch.

CJC-1295 with DAC is a modified growth hormone-releasing hormone analogue designed with a drug-affinity complex for albumin binding. The product remains research-only, and each presentation below is linked to its supplied analytical record.

01

Research class

DAC-modified GHRH receptor agonist
02

Documentation status

Investigational research compound
03

Reference CAS

Verify against lot COA
04

Physical form

White lyophilised powder

Research profile

GHRH signalling with an albumin-binding design.

The DAC modification is studied as a peptide half-life extension strategy. Research contrasts sustained receptor exposure with shorter-acting GHRH analogue formats.

GHRH
GHRH receptor pathway

The base analogue is designed to engage the growth hormone-releasing hormone receptor.

DAC
DAC modification

A maleimide-based drug-affinity complex supports albumin-associated residence in research models.

ALBUMIN
Sustained exposure

The format is used to examine prolonged signalling and receptor-occupancy questions.

Quality documentation

Certificate of Analysis

Choose a presentation to display the exact analytical record
supplied for that sample.

Select presentation
Selected COA

CJC-1295 with DAC · 5 mg

Purity99.614%
Measured content
6.79 mg
Identity
CJC-1295 with DAC
Lot
CJC1295DAC-5-1
Appearance
White Lyophilized Powder
Accession number
2606267392
Search code
Received
03/12/2026
Reported
3/14/2026
For laboratory research use only.

The supplied certificates state that the tested materials are intended for research use only and are not approved for human or veterinary use, diagnostic, therapeutic or clinical applications. Results are specific to the submitted samples. This page does not provide medical advice, dosing or administration instructions.